The Federal Trade Commission and seven states asked a federal judge in New York on Tuesday to hold Martin Shkreli in contempt of court. They say he has broken a lifetime ban on taking part in the drug business.

Shkreli, 43, became known as "Pharma Bro," the Guardian noted, after his company raised the price of the drug Daraprim by more than 5,000 percent, from $17.50 to $750 per tablet. In 2022, Judge Denise Cote banned him for life from the drug industry and ordered him to pay $64.6 million.

The new filing says Shkreli has traded stocks in at least 60 drug companies since he left prison in May 2022, STAT reported. Regulators say he also talked about those companies on livestreams and posts on YouTube, X and Reddit. During one livestream, he told viewers, "I'm showing you how to trade and invest in biotech," according to the FTC filing cited by the Guardian.

The FTC also says he used his livestreams to lead campaigns to short drug stocks. Shorting means betting that a company's share price will fall. He often based those bets on guesses that a company's drug trials would fail.

The regulators want the court to order Shkreli to sell his drug stocks and give up his trading profits, Courthouse News reported. They also asked for clear and growing penalties, including fines or jail, if he keeps breaking the order.

Daniel Guarnera, who leads the FTC's competition bureau, said the filing "should serve as notice" that the agency will enforce court orders, the Guardian reported. New York Attorney General Letitia James said, "A court-ordered lifetime ban isn't a suggestion," Courthouse News reported.

Shkreli has not yet filed a response in court.

What we know: Regulators say Shkreli traded stocks in at least 60 drug companies despite his lifetime ban.
What we don't: How the judge will rule, or how Shkreli will defend himself.